Meeting
2014 ASCO Annual Meeting
AUGMENT: A phase 3, randomized trial to compare efficacy and safety of lenalidomide plus rituximab versus placebo plus rituximab in patients with relapsed/refractory indolent non-Hodgkin lymphoma (NHL).
Authors
John Leonard
Weill Cornell Medical College, New York, NY
John Leonard , John G. Gribben , Marek Trneny , Phillip Scheinberg , Nurgul Kilavuz , Meera Patturajan , Pierre Fustier
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lymphoma and Plasma Cell Disorders
Track
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Sub Track
Lymphoma
Clinical Trial Registration Number
NCT01938001
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS8614)
DOI
10.1200/jco.2014.32.15_suppl.tps8614
Abstract #
TPS8614
Poster Bd #
299B
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).
First Author: Laurie Helen Sehn
Poster
2022 ASCO Annual Meeting
Updated interim analysis of the randomized phase 1b/3 study of tazemetostat in combination with lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma.
First Author: Connie Lee Batlevi
Poster
2023 ASCO Annual Meeting
Six-year safety and efficacy results from the CHRONOS-1 study of the PI3K inhibitor copanlisib in patients with relapsed or refractory follicular lymphoma.
First Author: Martin H. Dreyling
Poster
2023 ASCO Annual Meeting
ZUMA-22: A phase 3, randomized controlled study of axicabtagene ciloleucel (axi-cel) versus standard-of-care therapy in patients with relapsed or refractory (R/R) follicular lymphoma (FL).
First Author: Ian W. Flinn